Pay in 4 interest-free payments of $5.76 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
Published Phase 2 trial data (NEJM, 2023) demonstrated substantial reductions in body weight in some participants exceeding 20% over approximately 48 weeks making retatrutide one of the most potent agents currently in development for obesity and metabolic disease
Furthermore, research suggests that GLP-1 RAs confer a range of advantages to individuals without diabetes but with CVD
Individuals with higher toxic burdens from alcohol consumption, environmental exposures, or medication use may need several sessions before feeling meaningful relief
3, S7S19
US$ 21.84
US$ 28.65
US$ 25.92
US$ 21.19
